Company intelligence / Profile preview

H2Biologics

Shrewsbury, Massachusetts, United Statesh2biologics.com ↗

Ownership: Private
Development stage: Other

Overview

H2Biologics is developing a novel antibody-drug conjugate that links a human single domain antibody targeting mesothelin to human granzyme B, a serine protease. Preclinical studies have demonstrated potent anti-tumor activity in cell culture and xenograft models with lower systemic toxicity compared to conventional toxins. The lead program is in preclinical development for multiple solid tumors expressing mesothelin, including pancreatic and ovarian cancers.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateAntibodyProtein (Granzyme B-based immunoconjugate)
Industry: Biotech

Partnerships

Research Development Foundation/Clayton Foundation for Research (licensing and sponsored research agreement)University of Texas MD Anderson Cancer Center (originator of technology; research collaboration)

Beyond the preview

Go deeper on H2Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H2Biologics.